TABLE 2.
Average work productivity improvements over one year following initiation of adalimumab therapy
| Study visit | Weight*, % |
Pooled average productivity improvement according to study visit, mean change, % (95% CI) |
||
|---|---|---|---|---|
| Absenteeism | Presenteeism | TWPI | ||
| Week 0 (baseline) | 3.8 | 0 | 0 | 0 |
| Week 4 | 11.5 | −8.50 (−10.23 to −6.77) | −18.26 (−21.35 to −15.16) | −19.70 (−22.42 to −16.98) |
| Week 12 | 21.2 | −9.09 (−11.10 to −7.09) | −23.03 (−29.42 to −16.63) | −26.86 (−35.10 to −18.62) |
| Week 26 (mid-year) | 63.5 | −9.20 (−11.49 to −6.91) | −23.90 (−29.76 to −18.05) | −26.64 (−33.73 to −19.56) |
| Weighted average improvement over 1 year | – | −8.74 (−10.27 to −7.22) | −22.15 (−26.12 to −18.18) | −24.86 (−29.70 to −20.03) |
*
The estimate and 95% CI of average accumulated improvement over the one-year period after adalimumab initiation were derived based on a weighted average of the meta-analysis pooled estimates and standard errors of improvements at the week 4, week 12 and mid-year study visits. The weighting scheme was based on the assumption that patients experienced a constant rate of improvement from baseline to week 4, from week 4 to week 12, and from week 12 to the mid-year visit, and subsequently maintained the same average improvement from mid-year until week 52. TWPI Total work productivity impairment